FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2577306999> ?p ?o ?g. }

• W2577306999 endingPage "2748" @default.
• W2577306999 startingPage "2748" @default.
• W2577306999 abstract "Abstract Abstract 2748 Background: Mantle cell lymphoma (MCL) is a relatively rare but aggressive form of B-cell non-Hodgkin lymphoma (NHL) which is incurable with standard chemotherapy. Treatment options range from observation to allogeneic hematopoetic stem cell transplantation. The optimal therapy remains to be defined. Combination cytotoxic chemotherapy regimens containing anthracyclines such as R-CHOP or R-hyperCVAD used in other forms of lymphoma are clearly active. However, there appears to be a trade-off between intensity of the treatment and durability of the remission making delivery of the higher intensity, durable regimens difficult in some populations such as the elderly. Bortezomib (BOR) and lenalidomide (LEN) are commonly used in multiple myeloma and have also demonstrated activity in lymphoma including MCL. Rituximab (RIT) is effective in a broad array of CD20 positive lymphomas. The purpose of this study was to develop an effective, non-anthracycline containing treatment regimen that could be delivered to a broad patient population. Methods: Eligible patients had biopsy-proven MCL, ≤1 prior therapy, ECOG performance status of 0, 1, or 2, and adequate organ and bone marrow function. A brief phase I portion established the MTD. Dose limiting toxicities were defined as: grade 4 neutropenia or febrile neutropenia, grade 4 thrombocytopenia or platelet transfusion, uncontrolled grade 3 nausea or diarrhea, any clinically significant grade 3/4 treatment-related non-hematologic toxicity, or the inability to start Cycle 2 due to treatment related toxicity. Dose limiting toxicity in the phase I portion of this study occurred at 15mg of LEN on days 1–14 followed by 7 days of rest: 1pt with grade 4 neutropenia and grade 3 neuropathy, and 1 pt with grade 3 total body rash resulting in hospitalization. Based on these events phase II dosing was established at: LEN 10mg PO daily on days 1–14, BOR 1.3mg/m2 IV (days 1, 4, 8 and 11), and RIT 375mg/m2 (days 1, 8, and 15 of cycle 1; 375mg/m2on day 1 of subsequent cycles). Treatment was repeated every 21 days for a maximum of 6 cycles. Patients were assessed for response by International Lymphoma Response Criteria (Cheson 2007) after completing cycles 3 and 6. Phase II study objectives included: assessments of safety and tolerability of this three-drug regimen, and a preliminary estimate of efficacy. Results: Between June 2008 and May 2012, 22 patients were enrolled with a median age 66 years; (range 18–80) and are included in this analysis. Eighteen patients (82%) were stage IV at diagnosis, and 16 (78%) patients had not received prior treatment. At the time of this analysis, 11 patients (50%) completed treatment, and 3 additional patients (14%) remain active. Grade 3/4 thrombocytopenia and neutropenia were reported in 5 (23%) and 4 (18%) patients, respectively. Treatment related Grade 3/4 non-hematologic toxicity included: rash (32%), neuropathy (18%), dehydration (14%), and fatigue (14%). Three patients (14%) discontinued treatment due to toxicity (1 each: septic shock, neuropathy, cardiac ischemia/infarction). Eighteen patients were evaluable for response. The overall response rate was 82% (CR 32%, PR 50%). Of the 16 patients that received no prior treatment, the ORR was 75% (CR 25%, PR 50%). The median FU was 16 months (1–38) months. Kaplan-Meier estimates of all patients for progression-free and overall survival at 18 months are 61% and 79% respectively. Conclusion: The MTD of LEN in combination with BOR and RIT is less than LEN and BOR combinations in multiple myeloma. The three-drug regimen of RIT, BOR, and LEN is feasible in older as well as younger patients with MCL. Given the incidence of neuropathy, subcutaneous or less frequent IV dosing of BOR is worthy of investigation rather than the twice-weekly IV BOR used in this study. Preliminary estimates of efficacy indicate that this regimen is active, and warrants further study. Disclosures: Off Label Use: Off-lable use of Lenalidomide, and Bortezomib in the treatment of Mantle Cell Lymphoma." @default.
• W2577306999 created "2017-01-26" @default.
• W2577306999 creator A5000959540 @default.
• W2577306999 creator A5004557221 @default.
• W2577306999 creator A5009534746 @default.
• W2577306999 creator A5049400849 @default.
• W2577306999 creator A5050961257 @default.
• W2577306999 creator A5053655884 @default.
• W2577306999 creator A5065917441 @default.
• W2577306999 creator A5079398298 @default.
• W2577306999 date "2012-11-16" @default.
• W2577306999 modified "2023-10-18" @default.
• W2577306999 title "Rituximab, Lenalidomide, and Bortezomib in the First-Line or Second-Line Treatment of Patients with Mantle Cell Lymphoma a Phase I/II Trial." @default.
• W2577306999 doi "https://doi.org/10.1182/blood.v120.21.2748.2748" @default.
• W2577306999 hasPublicationYear "2012" @default.
• W2577306999 type Work @default.
• W2577306999 sameAs 2577306999 @default.
• W2577306999 citedByCount "9" @default.
• W2577306999 countsByYear W25773069992015 @default.
• W2577306999 countsByYear W25773069992016 @default.
• W2577306999 countsByYear W25773069992017 @default.
• W2577306999 countsByYear W25773069992022 @default.
• W2577306999 crossrefType "journal-article" @default.
• W2577306999 hasAuthorship W2577306999A5000959540 @default.
• W2577306999 hasAuthorship W2577306999A5004557221 @default.
• W2577306999 hasAuthorship W2577306999A5009534746 @default.
• W2577306999 hasAuthorship W2577306999A5049400849 @default.
• W2577306999 hasAuthorship W2577306999A5050961257 @default.
• W2577306999 hasAuthorship W2577306999A5053655884 @default.
• W2577306999 hasAuthorship W2577306999A5065917441 @default.
• W2577306999 hasAuthorship W2577306999A5079398298 @default.
• W2577306999 hasConcept C126322002 @default.
• W2577306999 hasConcept C141071460 @default.
• W2577306999 hasConcept C143998085 @default.
• W2577306999 hasConcept C2776063141 @default.
• W2577306999 hasConcept C2776364478 @default.
• W2577306999 hasConcept C2776694085 @default.
• W2577306999 hasConcept C2777063308 @default.
• W2577306999 hasConcept C2777478702 @default.
• W2577306999 hasConcept C2777525834 @default.
• W2577306999 hasConcept C2778336483 @default.
• W2577306999 hasConcept C2778850193 @default.
• W2577306999 hasConcept C2779338263 @default.
• W2577306999 hasConcept C2780653079 @default.
• W2577306999 hasConcept C2781413609 @default.
• W2577306999 hasConcept C2908647359 @default.
• W2577306999 hasConcept C2911091166 @default.
• W2577306999 hasConcept C71924100 @default.
• W2577306999 hasConcept C90924648 @default.
• W2577306999 hasConcept C99454951 @default.
• W2577306999 hasConceptScore W2577306999C126322002 @default.
• W2577306999 hasConceptScore W2577306999C141071460 @default.
• W2577306999 hasConceptScore W2577306999C143998085 @default.
• W2577306999 hasConceptScore W2577306999C2776063141 @default.
• W2577306999 hasConceptScore W2577306999C2776364478 @default.
• W2577306999 hasConceptScore W2577306999C2776694085 @default.
• W2577306999 hasConceptScore W2577306999C2777063308 @default.
• W2577306999 hasConceptScore W2577306999C2777478702 @default.
• W2577306999 hasConceptScore W2577306999C2777525834 @default.
• W2577306999 hasConceptScore W2577306999C2778336483 @default.
• W2577306999 hasConceptScore W2577306999C2778850193 @default.
• W2577306999 hasConceptScore W2577306999C2779338263 @default.
• W2577306999 hasConceptScore W2577306999C2780653079 @default.
• W2577306999 hasConceptScore W2577306999C2781413609 @default.
• W2577306999 hasConceptScore W2577306999C2908647359 @default.
• W2577306999 hasConceptScore W2577306999C2911091166 @default.
• W2577306999 hasConceptScore W2577306999C71924100 @default.
• W2577306999 hasConceptScore W2577306999C90924648 @default.
• W2577306999 hasConceptScore W2577306999C99454951 @default.
• W2577306999 hasIssue "21" @default.
• W2577306999 hasLocation W25773069991 @default.
• W2577306999 hasOpenAccess W2577306999 @default.
• W2577306999 hasPrimaryLocation W25773069991 @default.
• W2577306999 hasRelatedWork W136411592 @default.
• W2577306999 hasRelatedWork W1967461244 @default.
• W2577306999 hasRelatedWork W2063981148 @default.
• W2577306999 hasRelatedWork W2095669071 @default.
• W2577306999 hasRelatedWork W2400769328 @default.
• W2577306999 hasRelatedWork W2577306999 @default.
• W2577306999 hasRelatedWork W2586438189 @default.
• W2577306999 hasRelatedWork W2806380367 @default.
• W2577306999 hasRelatedWork W2810404518 @default.
• W2577306999 hasRelatedWork W3031718141 @default.
• W2577306999 hasVolume "120" @default.
• W2577306999 isParatext "false" @default.
• W2577306999 isRetracted "false" @default.
• W2577306999 magId "2577306999" @default.
• W2577306999 workType "article" @default.